Gilead to Acquire Tubulis for Up to $5B, Expanding Cancer ADC Capabilities
Headquartered in Munich, privately held Tubulis has developed next-generation ADC candidates based on its own conjugation, linker and payload technologies. The companies said Tubulis’ programs and platforms have broad potential across multiple tumor types, complementing Gilead’s development and commercialization expertise in oncology. The post Gilead to Acquire Tubulis for Up to $5B, Expanding Cancer ADC Capabilities appeared first on GEN - Genetic Engineering and Biotechnology News.
Original Source
Read the full article at Genengnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.